Progesterone for transgender women
Effect of micronised progesterone on sleep in transfeminine individuals: a prospective case-control study
Austin Health
38 participants
Nov 4, 2020
Interventional
Conditions
Summary
Transgender individuals seeking feminisation (transfeminine individuals) are treated with estrogen and anti-androgen (testosterone blocker) to align their physical appearance with their gender identity. There has been increasing interest in the potential use of progesterone for transfeminine individuals, given anecdotal reports of improved mood and breast development. This project is a trial of micronised progesterone in transfeminine individuals treated with estradiol therapy. We aim to establish the influence of progesterone on sleep, psychological distress and breast development.
Eligibility
Inclusion Criteria1
- Transfeminine individuals aged 18-70 years treated with estradiol for at least six months.
Exclusion Criteria9
- Contraindications to micronised progesterone.
- History of orchidectomy.
- Sunflower seed allergy.
- Known, suspected, or history of breast cancer.
- Active deep vein thrombosis, pulmonary embolism or history of these conditions.
- Active arterial thromboembolic disease or history of these conditions.
- Known liver dysfunction or disease.
- Recreational drug use, alcohol dependence, known HIV/AIDS or any disease that is likely lead to serious illness or death within the study period.
- Inability to understand sufficient English to provide informed consent or participate in the trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Micronised progesterone 100mg, oral capsule, daily for 3 months Adherence monitored through unused product return Group allocation is determined by participants' choice
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12620001130954